concept

NICOTINAMIDE

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about NICOTINAMIDE: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

202Connections

0Hypotheses

0Analyses

50Outgoing

50Incoming

No summary available yet. View on Wiki →

💡 Concept Info

Name	NICOTINAMIDE
Key Genes/Proteins	SIRT1, SIRT3, CSF1R, HDAC3
Related Diseases	ALZHEIMER'S DISEASE, ALZHEIMER, AUTOPHAGY, NEURODEGENERATION, AGING
Related Pathways	UNFOLDED PROTEIN RESPONSE
Linked Hypotheses	1 hypotheses

Wiki Pages (20)

Knowledge base pages for this entity

Pathway Diagram

graph TD
    NICOTINAMIDE["NICOTINAMIDE"]
    NICOTINAMIDE -->|"regulates"| SIRT1["SIRT1"]
    NICOTINAMIDE -->|"implicated in"| OBESITY["OBESITY"]
    NICOTINAMIDE -->|"inhibits"| SLC7A11["SLC7A11"]
    NICOTINAMIDE -->|"inhibits"| ROS["ROS"]
    NICOTINAMIDE -->|"interacts"| STEM_CELLS["STEM CELLS"]
    NICOTINAMIDE -->|"activates"| OXIDATIVE_STRESS["OXIDATIVE STRESS"]
    NEURON["NEURON"] -->|"inhibits"| NICOTINAMIDE
    GSH["GSH"] -->|"inhibits"| NICOTINAMIDE
    FERROPTOSIS["FERROPTOSIS"] -->|"inhibits"| NICOTINAMIDE
    INFLAMMATION["INFLAMMATION"] -->|"causes"| NICOTINAMIDE
    B_CELLS["B CELLS"] -->|"activates"| NICOTINAMIDE
    AGING["AGING"] -->|"implicated in"| NICOTINAMIDE
    GPX4["GPX4"] -->|"inhibits"| NICOTINAMIDE
    CATALASE["CATALASE"] -->|"target for"| NICOTINAMIDE

Outgoing (120)

Target	Relation	Type	Str
ALZHEIMER'S DISEASE	inhibits	disease	0.70
ALZHEIMER	causes	disease	0.70
AUTOPHAGY	modifies	phenotype	0.70
AUTOPHAGY	produces	phenotype	0.70
AUTOPHAGY	activates	phenotype	0.70
SIRT1	activates	gene	0.70
NEURODEGENERATION	exacerbates	phenotype	0.70
SIRT1	treats	gene	0.70
AGING	treats	phenotype	0.70
UNFOLDED PROTEIN RESPONSE	activates	pathway	0.70
SIRT3	treats	gene	0.70
OBESITY	impairs	disease	0.65
CELL DEATH	produces	phenotype	0.65
AUTOPHAGY	inhibits	phenotype	0.65
NRF2	activates	gene	0.65
NRF2	inhibits	gene	0.65
SUBSTANTIA NIGRA	protects_against	brain_region	0.65
SUBSTANTIA NIGRA	inhibits	brain_region	0.65
BREAST CANCER	inhibits	disease	0.65
METFORMIN	activates	drug	0.65
METFORMIN	treats	drug	0.65
OXIDATIVE STRESS	interacts_with	phenotype	0.65
INFLAMMATION	produces	phenotype	0.65
OXIDATIVE STRESS	inhibits	phenotype	0.65
MACROPHAGES	activates	cell_type	0.65
MITOPHAGY	degrades	phenotype	0.65
ATP	participates_in	phenotype	0.55
PINK1	associated_with	gene	0.50
AMPK	associated_with	gene	0.50
MTOR	associated_with	gene	0.50
TH	associated_with	gene	0.50
CSF1R	associated_with	gene	0.50
ASTROCYTE	associated_with	cell_type	0.50
NEURON	associated_with	cell_type	0.50
HDAC3	associated_with	gene	0.50
TET2	associated_with	gene	0.50
ATG5	associated_with	gene	0.50
ATG7	associated_with	gene	0.50
UBIQUITIN	associated_with	protein	0.50
PARKINSON	associated_with	disease	0.50
SIRT3	associated_with	gene	0.50
SENESCENCE	associated_with	phenotype	0.50
HO-1	associated_with	gene	0.50
CSF	associated_with	phenotype	0.50
INFLAMMATION	associated_with	phenotype	0.45
CELL DEATH	associated_with	phenotype	0.45
OBESITY	associated_with	disease	0.45
SIRT1	associated_with	gene	0.45
FERROPTOSIS	associated_with	phenotype	0.45
CHOLESTEROL	associated_with	phenotype	0.45

Incoming (82)

Source	Relation	Type	Str
CSF1R	inhibits	gene	0.70
HDAC3	inhibits	gene	0.70
AGING	inhibits	phenotype	0.70
NAD	mediates	gene	0.65
NAD	promotes	gene	0.65
NAD	contributes_to	gene	0.65
CD38	regulates	gene	0.65
NAD	regulates	gene	0.65
NAD	treats	gene	0.65
CD38	activates	gene	0.65
MACROPHAGE	expressed_in	cell_type	0.65
NAD	interacts_with	gene	0.65
NAD	inhibits	gene	0.65
NAD	stabilizes	gene	0.65
CHOLESTEROL	causes	phenotype	0.65
AMYLOID	treats	protein	0.65
FIBROBLASTS	produces	cell_type	0.65
FERROPTOSIS	regulates	phenotype	0.65
NEURONS	treats	cell_type	0.65
KYNURENINE	activates	phenotype	0.65
METFORMIN	synergizes_with	drug	0.60
HDAC3	synergizes_with	gene	0.60
NEURON	inhibits	cell_type	0.50
GSH	inhibits	gene	0.50
FERROPTOSIS	inhibits	process	0.50
NEURODEGENERATION	associated_with	phenotype	0.50
PROTEIN AGGREGATION	associated_with	phenotype	0.50
NEUROINFLAMMATION	associated_with	phenotype	0.50
PARKINSON'S DISEASE	associated_with	disease	0.50
UNFOLDED PROTEIN RESPONSE	associated_with	pathway	0.50
SUBSTANTIA NIGRA	associated_with	brain_region	0.50
HISTONE ACETYLATION	associated_with	phenotype	0.50
DOPAMINERGIC NEURONS	associated_with	cell_type	0.50
BREAST CANCER	associated_with	disease	0.50
CEREBROSPINAL FLUID	associated_with	phenotype	0.50
OXIDATIVE STRESS	associated_with	phenotype	0.45
MITOCHONDRIAL DYSFUNCTION	associated_with	phenotype	0.45
ALZHEIMER'S DISEASE	associated_with	disease	0.45
ATP	associated_with	phenotype	0.45
CELL DEATH	associated_with	phenotype	0.45
INFLAMMATION	associated_with	phenotype	0.45
FERROPTOSIS	associated_with	phenotype	0.45
CHOLESTEROL	associated_with	phenotype	0.45
AUTOPHAGY	associated_with	phenotype	0.45
GPX4	associated_with	gene	0.45
NEURONS	associated_with	cell_type	0.45
AMYLOID	associated_with	protein	0.45
CANCER	associated_with	disease	0.45
FIBROBLASTS	associated_with	cell_type	0.45
MACROPHAGES	associated_with	cell_type	0.45

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

NICOTINAMIDE

Understanding Entity Pages

Wiki Pages (20)

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Novel Therapy Index

CBS/PSP Supplements Guide

Atypical Parkinsonism

Parthanatos in Neurodegeneration

Section 148: Advanced Nutritional Biochemistry in CBS/PSP

PD Combination Therapy Matrix

Therapeutics

Mitochondrial Quality Control

Energy Metabolism Dysfunction Comparison Across Neurodegenerative Diseases

Mitophagy Pathway in Neurodegeneration

Synaptic Vesicle Trafficking in Parkinson's Disease

Epigenetic Dysregulation in Neurodegeneration

A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Neuroprotection Strategies in Neurodegeneration

Gene-Mechanism-Therapy Causal Chains